BTIG Upgrades Neogenomics (NEO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016
October 26, 2016 7:00 AM EDTFT. MYERS, Fla., Oct. 26, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2016.
Third Quarter 2016 Highlights:
142% increase in consolidated revenue to $60.8 million 150% increase in clinical genetic testing volume(1) Diluted EPS of ($0.07) per share and Adjusted Diluted EPS(2) of $0.04 per share Year-to-date cash flow from operations of $21.7 millionConsolidated revenue for the third quarter was $60.8 million, an increase of 142% over the same period last... More
